Allurion Technologies (NYSE:ALUR) received U.S. Food and Drug Administration (FDA) premarket approval (PMA) for its Allurion Gastric Balloon System, marking a significant expansion into the U.S. obesity care market.
Parts of New York City got up to 28 inches of snow during this blizzard, but most of the transit system is up and running. There are reduced schedules. MTA Chair and CEO Jano Lieber gives an update on Bloomberg Surveillance.
Federal Reserve Governor Christopher Waller said his decision on whether to support an interest-rate cut at the US central bank's next policy meeting on March 17-18 will depend on upcoming labor-market data. Waller spoke Monday at an event in Washington with the National Association for Business Economics
In times of uncertainty, we often look for something solid to hold onto. Lately, it seems the world’s investors have decided that “something solid” is, quite literally, gold.
The metal’s soaring price is more than just a market trend; it's a global barometer of anxiety.
When faith in currencies, governments, and traditional financial systems begins to waver, we see a familiar flight to the perceived safety of this timeless asset.
Well, pull out the party hats and dust off the stock tickers.
Lithium, the commodity that investors and analysts had all but left for dead in the great market purge of 2023-2024, is back.
The stock market has long treated Tesla (NASDAQ:TSLA) less as a traditional automaker and more as a futuristic technology cult, with its valuation soaring on the gravitational pull of its CEO, Elon Musk.
This persistent "Musk Premium" has burned countless short-sellers.
Bitcoin has vaporised more than US$800 billion in its latest crash and sucked US$1 trillion out of the broader crypto market.
With nearly US$2 trillion in market value and rising allocations from Wall Street firms, ETFs, pension funds, and insurers, Bitcoin is increasingly woven into traditional finance.
U.S. Customs and Border Protection (CBP) will officially stop collecting billions in trade duties at 12:01 a.m. EST on Tuesday, following a landmark Supreme Court ruling that declared President Donald Trump’s use of emergency powers to levy tariffs illegal.
The U.S. Supreme Court delivered a historic blow to President Donald Trump’s economic agenda Friday, ruling 6-3 that the administration overstepped its constitutional authority by using a national emergency statute to impose sweeping global tariffs.
The January US jobs report surprised to the upside, adding 130,000 roles as unemployment dipped to 4.3% and wages stayed contained.
Washington has pulled itself back from the brink, passing a $1.2 trillion stop-gap deal that reopened most of the US government after days of disruption.
Federal Reserve Governor Christopher Waller said his decision on whether to support an interest-rate cut at the US central bank's next policy meeting on March 17-18 will depend on upcoming labor-market data. Waller spoke Monday at an event in Washington with the National Association for Business Economics
AMC Entertainment Holdings(NYSE:AMC), the world's largest theatrical exhibition company, reported fourth-quarter and full-year 2025 results on February 23, 2026, reflecting a challenging yet stabilizing environment for the movie theater industry following years of pandemic disruption and uneven film slates.
Freshpet (NASDAQ:FRPT) reported record fourth-quarter and full-year 2025 results on Monday, crossing the billion-dollar revenue mark for the first time in the company's history.
The U.S. Supreme Court delivered a historic blow to President Donald Trump’s economic agenda Friday, ruling 6-3 that the administration overstepped its constitutional authority by using a national emergency statute to impose sweeping global tariffs.
Albuquerque, New Mexico-based Array Technologies (NASDAQ:ARRY), a leading provider of solar tracking systems and related products for utility-scale and distributed generation solar projects, reported fourth-quarter and full-year 2025 financial results on February 20, 2026, alongside 2026 guidance reflecting its streamlined focus on core solar operations following major spectrum asset sales.
AstraZeneca (NASDAQ:AZN) announced on Friday that the U.S. Food and Drug Administration (FDA) has approved its BTK inhibitor, Calquence (acalabrutinib), in combination with venetoclax as the first all-oral, fixed-duration treatment for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).